Oncolytics Biotech jumps after pancreatic cancer therapy gets regulatory nod

Oncolytics Biotech

15/01/2025 13:05

** U.S.-listed shares of Oncolytics Biotech  ONC.TO 
 ONCY.O  rise 35.8% to $1.10 premarket
    ** ONCY says its pancreatic cancer therapy, pelareorep, has
received regulatory approval to continue patient enrollment
    ** ONCY is evaluating pelareorep in combination with
chemotherapy regimen Folfirinox and immunotherapy atezolizumab
    ** ONCY says it will move forward with full enrollment of 30
newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients
in the first stage
    ** All 5 brokerages covering the stock rate it "buy"
    ** ONCY fell ~31% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))